Recursion Pharmaceuticals (RXRX) director granted 5,109 Class A shares

Rhea-AI Filing Summary

Dar Zavain reported acquisition or exercise transactions in this Form 4 filing.

RECURSION PHARMACEUTICALS, INC. director Zavain Dar received an award of 5,109 shares of Class A Common Stock. The shares were issued at no cash cost to him and were granted under the company’s Outside Director Compensation Policy. Following this award, he directly holds 240,764 Class A shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Dar Zavain

Role null

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	5,109	$0.00	--

Holdings After Transaction: Class A Common Stock — 240,764 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares granted: 5,109 shares Grant price per share: $0.0000 Shares held after transaction: 240,764 shares

3 metrics

Shares granted 5,109 shares Class A Common Stock grant to director on 2026-07-01

Grant price per share $0.0000 Reported transaction price per share for the award

Shares held after transaction 240,764 shares Total direct Class A holdings following the grant

Key Terms

Class A Common Stock, Grant, award, or other acquisition, Outside Director Compensation Policy

3 terms

Class A Common Stock financial

"security_title: "Class A Common Stock""

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Outside Director Compensation Policy financial

"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 05:16 PM Accepted by SEC EDGAR 07/02/2026 - 05:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dar Zavain

(Last) (First) (Middle)

C/O RECURSION PHARMACEUTICALS

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY UTAH 84101

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	07/01/2026		A(1)		5,109	A	$0	240,764	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

Remarks:

	/s/ Jonathan Golightly, attorney-in-fact	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did RXRX director Zavain Dar report on this Form 4?

Zavain Dar reported receiving 5,109 shares of RECURSION PHARMACEUTICALS Class A Common Stock. The transaction was coded as a grant or award, meaning it was a compensation-related share issuance rather than an open-market purchase or sale.

Was the RXRX Form 4 transaction an open-market buy or sell of shares?

The RXRX Form 4 does not show an open-market buy or sell. It reports an "A" code transaction, described as a grant, award, or other acquisition of shares, issued under the company’s Outside Director Compensation Policy.

How many RXRX shares did Zavain Dar hold after this reported award?

After receiving the 5,109-share award, Zavain Dar directly held 240,764 shares of RECURSION PHARMACEUTICALS Class A Common Stock. This figure reflects his total direct ownership immediately following the compensation-related transaction.

What does the footnote in the RXRX Form 4 say about the share grant?

The Form 4 footnote explains that the 5,109 shares were issued pursuant to RECURSION PHARMACEUTICALS’ Outside Director Compensation Policy. This clarifies the award as standard director compensation rather than a discretionary trading decision.

How is the Form 4 transaction for RXRX categorized in SEC terms?

The Form 4 categorizes the RXRX transaction with code "A" for a grant, award, or other acquisition. It is labeled as non-derivative Class A Common Stock, with the transaction direction marked as an acquisition, and the ownership reported as direct.